Skip to Content
Merck
All Photos(1)

Documents

1481204

USP

Oxaliplatin

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N′)[ethanedioata(2--)-O,O’]platinum

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C8H14N2O4Pt
CAS Number:
61825-94-3
Molecular Weight:
397.29
MDL number:
MFCD00866327
UNSPSC Code:
41116107
PubChem Substance ID:
329750629
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

oxaliplatin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1O[Pt]OC1=O.N[C@@H]2CCCC[C@H]2N

InChI

1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1

InChI key

ZROHGHOFXNOHSO-BNTLRKBRSA-L

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Oxaliplatin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Oxaliplatin Injection
  • Oxaliplatin for Injection

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000271

Oxaliplatin, European Pharmacopoeia (EP) Reference Standard

Y0000275

Dichlorodiaminocyclohexaneplatinum, European Pharmacopoeia (EP) Reference Standard

Y0000273

Oxaliplatin impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000274

Oxaliplatin impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000272

Oxaliplatin impurity B, European Pharmacopoeia (EP) Reference Standard

1481226

Oxaliplatin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1481215

Oxaliplatin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1481237

Oxaliplatin Related Compound C, United States Pharmacopeia (USP) Reference Standard

1481248

Oxaliplatin Related Compound D, United States Pharmacopeia (USP) Reference Standard

1481306

Oxaliplatin System Suitability, United States Pharmacopeia (USP) Reference Standard

1481260

Oxaliplatin Related Compound F, United States Pharmacopeia (USP) Reference Standard

PHR2545

Oxaliplatin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Health hazardCorrosion
GHS08,GHS05

Signal Word

Danger

Hazard Classifications

Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

L B J van Iersel et al.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 40(11), 1557-1563 (2014-08-16)
To improve isolated hepatic perfusion (IHP), we performed a phase I dose-escalation study to determine the optimal oxaliplatin dose in combination with a fixed melphalan dose. Between June 2007 and July 2008, 11 patients, comprising of 8 colorectal cancer and
Maire F Osborn et al.
ACS chemical biology, 9(10), 2404-2411 (2014-07-24)
With the importance of RNA-based regulatory pathways, the potential for targeting noncoding and coding RNAs by small molecule therapeutics is of great interest. Platinum(II) complexes including cisplatin (cis-diamminedichloroplatinum(II)) are widely prescribed anticancer compounds that form stable adducts on nucleic acids.
Hirofumi Yasui et al.
Journal of cancer research and clinical oncology, 141(1), 153-160 (2014-08-12)
The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint. The overall survival (OS) data were immature at
Jennifer R Deuis et al.
Neuro-oncology, 16(10), 1324-1332 (2014-04-10)
Peripheral neuropathy is the major dose-limiting side effect of cisplatin and oxaliplatin, and there are currently no effective treatments available. The aim of this study was to assess the pharmacological mechanisms underlying chemotherapy-induced neuropathy in novel animal models based on
Hans-Joachim Schmoll et al.
The Lancet. Oncology, 15(13), 1481-1492 (2014-12-03)
Oxaliplatin-based adjuvant therapy is the standard of care for stage III colon cancer. Adjuvant capecitabine with or without oxaliplatin versus leucovorin and fluorouracil with or without oxaliplatin has not been directly compared; therefore, we aimed to analyse the efficacy and
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service